This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's. This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau. The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
CTAD will feature sessions and keynotes from several ADDF-funded investigators whose work is centered around the biology of aging, which is based on our understanding that novel treatments, diagnostics, and prevention strategies are needed to conquer this disease.
'We're at the dawn of a new era in Alzheimer's research where we have the first class of drugs on the market targeting amyloid, but there is a broader consensus on the need to develop multiple new therapies based on the biology of aging that can be used in combination with these anti-amyloid drugs,' says Dr.
Chair:
Roundtable: 'Forging the Path Forward: Capitalizing on Recent Alzheimer's Momentum through Strategic Investments in Novel Therapeutics' on
Moderator:
Panelists:
Additional sessions from ADDF-funded investigators will include: Keynote: 'Alzheimer's Disease: The Drug Development Pipeline and Emerging Therapies' with Dr.
Late Breaker: 'PrecivityAD2 blood test: An analytically and clinically validated test combining p-tau217/np-tau217 and A42/40 ratios to identify brain amyloid' with C2N on
Late Breaker: 'Evidence that Lumipulse G pTau217 Plasma measurements have the ability to quantitatively assess Tau stage and burden' with
Contact:
Email: info@alzdiscovery.org
Tel: 212.901.800
(C) 2023 Electronic News Publishing, source